ImmunoGen Message Board - Msg: 16709606

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ImmunoGen

IMGN 31.23

0.0%

Feb 26 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Icebrg who wrote (4237)	11/27/2001 3:36:18 PM
From: Icebrg	Read Replies (1) of 5665

We made it to the Financial Times. Or at least a part of us did. The pink paper today includes a biotech survey insert. They do these kind of things all the time. Mostly about retail banking in Nigeria or the real estate business in Afghanistan. But today it was time to have a look at the biotech industry. The survey is supposed to be available on the net too. At the URL news.ft.com But when one clicks on the appropriate link a more or less blank page comes up. Perhaps it is still work in progress. Or a mistake in the lay-out. Those things happen when the HTML-tags are misplaced. Anyhow and to the subject of the thread. They do carry an article titled: It has taken 25 years to arm the body's smart bomb. They have also identified ImmunoGen. Or sort of. Here is what they have to say about the board's favorite company. Other companies are taking the concept of the magic bullet one step further, by attaching toxic chemicals or radioactive isotopes like warheads to antibodies. British Biotech and ImmunoGen, the US company, have attached an antibody to DM1, an inactive version of a chemotherapy drug that is so toxic that it previously could never be used in conventional treatment. Now DM1 only becomes active when it is locked on to cancer cells. The companies hope it will control tumors without triggering the devastating side effects of conventional chemotherapy. Close, but absolutely no cigar. The author, in the preceding paragraph, writes about Herceptin and its advantages, but seems to ignore the fact that a new sharper DM-1 conjugated version is in the works. And GSK's efforts with huC242-DM1 seems to have passed him completely. Anyhow, it is good with some press even if the subject seems slightly misunderstood or overlooked. Ice

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next